Characterization of metabolic rewiring and identification of potential therapeutic targets in CBFA2T3-GLIS2-dependent acute megakaryoblastic leukemia

CBFA2T3-GLIS2依赖性急性巨核细胞白血病代谢重连的表征和潜在治疗靶点的鉴定

• 批准号: 476710
• 负责人: Capdevielle Caroline
• 金额: $ 3.28万
• 依托单位: Centre de recherche de l'Hôpital Maisonneuve-Rosemont (Montral)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-10-01 至 2024-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=476710&lang=en
• 关键词: Amkl; Cbfa2t3-Glis2; Gene Fusion; Metabolism; Pediatric Cancer; Therapeutic Targets

Pediatric acute megakaryoblastic leukemia (AMKL) is a rare, aggressive and poorly understood childhood hematology cancer. Indeed, it represents only 10 % of pediatric acute myeloid leukemias (AML) and is associated with poor prognosis. It is characterized

小儿急性巨核细胞白血病（AMKL）是一种罕见的，侵袭性和了解甚少的儿童血液学癌症。事实上，它仅占儿童急性髓性白血病（AML）的10%，并且与预后不良相关。它的特点